Infinity Announces Presentations at Upcoming Lung Cancer Meeting

| Source: Infinity Pharmaceuticals, Inc. Infinity Pharmaceuticals, Inc.

CAMBRIDGE, Mass., Feb. 23, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that presentations featuring two of its clinical candidates will be made at the 10th Annual Targeted Therapies of the Treatment of Lung Cancer meeting to be held February 24-27, 2010 in Santa Monica, Calif.

  • Lecia V. Sequist, M.D., M.P.H., of Massachusetts General Hospital Cancer Center and Assistant Professor of Medicine at Harvard Medical School, will discuss Infinity's Phase 2 study of its novel heat shock protein 90 (Hsp90) inhibitor, IPI-504, in patients with advanced non-small cell lung cancer. The presentation entitled, "IPI-504: a Novel HSP-90 Inhibitor," will be given on February 25, 2010 at 8:45 a.m. PST.
     
  • Charles Rudin, M.D., Ph.D., Associate Director for Clinical Research at Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, will give an overview of Infinity's novel Hedgehog pathway inhibitor, IPI-926, which is being evaluated in Phase 1 development. The presentation, entitled "IPI-926: Targeting Malignant Activation of the Hedgehog Pathway," will be given on February 27, 2010 at 11:35 a.m. PST.

The slides from each presentation will be accessible in the Publications Archive section of the company's website at http://www.infi.com after the presentations have been given.

About Infinity Pharmaceuticals, Inc.

Infinity is an innovative cancer drug discovery and development company seeking to discover, develop, and deliver to patients best-in-class medicines for the treatment of cancer and related conditions. Infinity combines proven scientific expertise with a passion for developing novel small molecule drugs that target emerging disease pathways. Infinity's programs in the inhibition of the Hsp90 chaperone system, the Hedgehog pathway and fatty acid amide hydrolase are evidence of its innovative approach to drug discovery and development. For more information on Infinity, please refer to the company's website at http://www.infi.com.



            








        

            

                

                    
Mot-clé

                            
                                PHARMACEUTICALS
                            
                            
                                MEDICAL
                            

                



        




    

        

        
Coordonnées